As PARP-1 has broad synergistic effect with other targets in anti-tumor studies (Chang et al., 2021; Wei et al., 2021), these compounds also provide the alternative active scaffold for the further multi-targeting drug design by combining PARP-1 with LdTop1 or α-glucosidase. The gene discussed is PARP1; the disease is neoplasm.